Eledon Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
Eledon Pharmaceuticals, Inc. (ELDN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $3.57 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-19
- Eledon Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $3.57M, a 26.78% increase from fiscal 2024.
- Eledon Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $2.82M, a 287.23% increase from fiscal 2023.
- Eledon Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $728.00K, a 26.17% decline from fiscal 2022.
- Eledon Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $986.00K, a 51.46% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2025-12-31 | $3.57M 10-K · filed 2026-03-19 |
| 2024-12-31 | $2.82M 10-K · filed 2026-03-19 |
| 2023-12-31 | $728.00K 10-K/A · filed 2025-08-14 |
| 2022-12-31 | $986.00K 10-K/A · filed 2024-08-19 |
| 2021-12-31 | $651.00K 10-K · filed 2023-03-30 |
| 2020-12-31 | $252.00K 10-K · filed 2022-03-24 |
| 2019-12-31 | $141.00K 10-K · filed 2021-03-31 |
| 2018-12-31 | $72.00K 10-K · filed 2020-03-17 |
| 2017-12-31 | $135.00K 10-K · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |